Parkinson’s Disease: Start-Ups Seek Breakthroughs And Money
Parkinson’s disease remains a significant undermet, attractive opportunity for drug developers, including early-stage biotechs. Profiles of MentiNova, Parkure and Prexton Therapeutics.
Parkinson’s disease remains a significant undermet, attractive opportunity for drug developers, including early-stage biotechs. Profiles of MentiNova, Parkure and Prexton Therapeutics.